NCT07704099 Rinvatercept Muscular Dystrophy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07704099—Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07704099 is a hot trial to watch

Muscular Dystrophy is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. NCT07704099 is notable because it tests Rinvatercept in a Phase 2 design while Number of participants with treatment-emergent adverse events (TEAEs and serious adverse events (SAEs) serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment. Enrollment of 36 participants across the reported study geography shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

• Primary: Number of participants with treatment-emergent adverse events (TEAEs and serious adverse events (SAEs) — Up to approximately 3 years
• Secondary: KER-065 serum concentration by visit, as appropriate — Up to Week 100
• Secondary: Number and proportion of participants with treatment-emergent ADA (antidrug antibody) by visit — Up to Week 100
• Secondary: Change from baseline by visit in bone mineral density (BMD), fat mass, and lean body mass, as measured by dual- energy X-ray absorptiometry (DXA) — Up to Week 96
• Secondary: Change from baseline by visit in muscle volume and intramuscular fat by skeletal muscle MRI — Up to Week 96

Benchmark readouts in the surrounding field

• Vamorolone for Duchenne Muscular Dystrophy (Phase 2): TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028); TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028)
• Safety and Efficacy of Tamoxifen in Patients with Duchenne muscular dystrophy: open Label Extension of TAMDMD Trial (Phase 3): SAE = 9.0 %
• Impact and Interplay of Corticosteroid Regimen and Exercise Training on DMD Muscle Function (Phase 2): Change in BMI(Mean) = 1.8 kg/m^2 (Standard Deviation, 1.9); Change in BMI(Mean) = 0.67 kg/m^2 (Standard Deviation, 1.4)

These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Rinvatercept (Phase 2; Activin A x MSTN x TGF-β)

Company & Deal Intelligence context: Keros Therapeutics, Inc. — http://www.kerostx.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07704099 is a focused lens on Muscular Dystrophy development. Its value will be determined by whether Rinvatercept can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.